# ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors

> **NCT04737174** · PHASE2 · WITHDRAWN · sponsor: **ES Therapeutics Australia Pty Ltd**

## Conditions studied

- Epilepsy; Seizure

## Interventions

- **DRUG:** ES-481

## Key facts

- **NCT ID:** NCT04737174
- **Lead sponsor:** ES Therapeutics Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-25
- **Primary completion:** 2021-10
- **Final completion:** 2022-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of identifiable patients
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04737174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04737174, "ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04737174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*